John Thero

12 results

Vascepa is aiming to become the first prescription drug for people at risk of stroke or heart attack who continue to have high levels of harmful blood fats despite being on treatment with statins

Shares in US-listed Irish biotech Amarin surged in New York after it upgraded its profit forecasts. A strong update for the prospects of its cardiova(...)

John Thero: ‘I am pleased that Amarin’s significant progress and innovative work is recognised by this award.’ Photograph: Cyril Byrne

Fish oil drug specialist Amarin has been recognised for the breakthrough results for its one medicine, Vascepa, as a cardiovascular therapy. John The(...)

The FDA grants priority review only to drugs that have the potential to offer significant improvement in the treatment of serious conditions.

Shares in Irish drug company Amarin jumped 14 per cent after its Vascepa drug was fast-tracked for approval as a treatment for reducing the risk of he(...)

US FDA approval would allow Amarin to pitch its fish-oil drug direct to the consumer rather than solely through the medical practitioner channel. File photograph: Getty

Shareholders tuning into Amarin’s annual shareholders’ meeting in Dublin on Monday had plenty to cheer them. Shares in the company have risen more th(...)

Amarin chief executive John Thero: ‘Our guidance is for 50 per cent greater growth over the prior year’

Irish drug company Amarin will seek European approval for its cardiovascular drug Vascepa before the end of the year. The drug is in the process of s(...)

Aryzta had an unremitting bad year and was the  standout corporate loser of 2018. Photograph: Reuters

It was another year of mixed fortunes in corporate Ireland. The economy continues to be the fastest growing in Europe while the live register fell to (...)

Amarin chief executive John Thero: detailed results for fish-oil drug Vascepa confirm initial figures for its success

Amarin, a one-drug Irish company, will discover the market’s verdict on its prospects Monday after presenting detailed data on a very successful clini(...)

Analysts said Amarin could now expect sales of up to $2.7 billion annually for a drug that currently brings in $230 million in revenue. Photograph: iStock

Shares in Irish biotechnology company Amarin soared as the company reported unexpectedly strong results from a clinical trial for its omega-3 fish oil(...)

Irish biopharma group Amarin has reported 85 per cent growth in net revenue from its heart drug Vascepa. The company reported sales of $32.8 million(...)

Amarin chief executive and president  John Thero. Photograph: Cyril Byrne / THE IRISH TIMES

A small one-product Irish pharmaceutical company has secured a landmark victory over the US drugs regulator in a New York court. US district ju(...)

  • 1
  • 2
  • Next
  • Last »